HOUSTON, October 23, 2023 Kiromic BioPharma, Inc. (OTC PINK: KRBP) ("Kiromic" or the "Company"), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the execution of a clinical trial agreement with Beverly Hills Cancer Center (BHCC) to conduct its Deltacel-01 Phase 1 Study. Pursuant to the agreement, BHCC, one of Southern California’s esteem
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma 95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 data cut-of
Biopharma Stock News - Soleno Therapeutics (NASDAQ: SLNO) Announces Positive Statistically Significant Top-line Results From Randomized Withdrawal Period of Study C602 of DCCR for Prader-willi Syndrome
EQSAdhoc Eckert & Ziegler Strahlen und Medizintechnik AG Key word Contract Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium177 with POINT Biopharma 25Sep202